VANCOUVER, British Columbia, June 15, 2010 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types). The purpose of the study was to evaluate if Visudyne® (verteporfin PDT; Novartis Pharma AG, QLT Inc.) (either reduced- or standard-fluence) combined with Lucentis® (ranibizumab; Novartis Pharma AG, Genentech Inc.) was not inferior (with a non-inferiority margin of seven letters) to monthly Lucentis monotherapy with respect to the mean change from baseline in visual acuity (VA) and to evaluate the proportion of patients with a Lucentis treatment-free interval of at least three months duration after Month 2 until Month 11.
